Hi Evaluate,
I see it this way as well.
We will compare the time from recurring after soc to dead and on the other side recurring after SOC , followed bij DC-Vax, to dead.
And then the percentages alive ofcourse.
Since SOC alone will have about 5% survival (5 years), it won't be difficult i.m.o. to prove SOC recurring + DC-Vax will be much better.
That's what they are looking for i think.
But will it be enough to get label extension or approval for recurring tumors with the number of patients in this trial we have?
Let's hope so.
Best to you
Market Data 
Markets 
AI
